MedTrace Logo

Open-label Extension Study of ADP101

NCT05243719 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2024-03-26

No results posted yet for this study

Summary

This is an open-label, safety extension study for participants who participated in the Harmony study (protocol ADP101-MA-01).

Conditions

Interventions

BIOLOGICAL

ADP101

Active dry powder formulation at various volumes.

Sponsors & Collaborators

  • Alladapt Immunotherapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Mei-Lun Wang, MD · VP of Clinical Development, Alladapt Immunotherapeutics, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Max Age
57 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-14
Primary Completion
2024-02-27
Completion
2024-02-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05243719 on ClinicalTrials.gov